Skip to main
RMD

ResMed (RMD) Stock Forecast & Price Target

ResMed (RMD) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 18%
Buy 45%
Hold 36%
Sell 0%
Strong Sell 0%

Bulls say

ResMed demonstrates a robust financial outlook supported by a consistent increase in cash returns to shareholders, exemplified by a dividend increase and an aggressive share repurchase strategy. The company has experienced a significant year-over-year revenue increase, with U.S., Canada, and LATAM masks and other revenue rising by 12% in the fourth quarter of fiscal 2025, outperforming expectations by 2%. Additionally, the strategic focus on digital health initiatives positions ResMed to drive long-term growth and sustainability amid an expanding market driven by rising sleep apnea diagnoses and demographic trends.

Bears say

ResMed faces a negative outlook primarily due to concerns regarding the potential impact of GLP-1 drug uptake on the growth of its mask and device segments, which may disrupt future revenues from positive airway pressure (PAP) volumes. Despite the company currently outgrowing the market, the findings from a comprehensive survey of sleep specialists suggest that these disruptions could significantly affect sales in the medium term. This indicates that while ResMed operates in a structurally growing market due to an increase in sleep apnea diagnoses and related trends, external factors may hinder its financial performance moving forward.

ResMed (RMD) has been analyzed by 11 analysts, with a consensus rating of Buy. 18% of analysts recommend a Strong Buy, 45% recommend Buy, 36% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ResMed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ResMed (RMD) Forecast

Analysts have given ResMed (RMD) a Buy based on their latest research and market trends.

According to 11 analysts, ResMed (RMD) has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $294.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $294.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ResMed (RMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.